Detalles de la búsqueda
1.
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
Haematologica
; 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38356463
2.
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Haematologica
; 109(2): 543-552, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37560813
3.
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.
Clin Lymphoma Myeloma Leuk
; 23(10): e341-e347, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37517875
4.
Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.
Clin Lymphoma Myeloma Leuk
; 22(4): e241-e249, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774462
5.
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
Clin Cancer Res
; 28(21): 4771-4781, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36074126
6.
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Clin Lymphoma Myeloma Leuk
; 21(6): 413-420, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33741302
7.
Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
Amyloid
; 27(3): 163-167, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32106714
Resultados
1 -
7
de 7
1
Próxima >
>>